Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
News Go to news feed
SMI reaches record high, Sandoz leads gainers
The Swiss stock market closed higher: the SMI rose 1.2% to 14,757 points and hit an intraday record at 14,862 points. The market was supported by the Fed and ECB decisions to keep key interest rates unchanged. Sandoz gained 4.4%, the biggest mover after a rebound from the previous day's losses; UBS rose 2.9% following positive analyst comments, Novartis gained 2.4%, and Logitech extended its prior-day losses. » More on finanzen.net
Sandoz raises margin target and reduces revenue growth forecast for 2026
Sandoz reported a revenue increase of 8% to USD 8.7 billion for the first nine months, driven by double-digit gains in the biosimilars business while generics suffered from price declines. For 2026, management now expects constant‑currency revenue growth of 5–6% instead of the previously forecast mid‑to‑high single‑digit range. The core EBITDA margin has been raised to 23.0–23.5% (prior year 21.7%), attributed to a more favorable revenue mix and stronger operational performance. The stock fell sharply as a result. » More on finanzen.net
Sandoz plant in Kundl faces closure due to cheap competition from China
The Sandoz plant in Kundl is the last fully integrated penicillin factory in Europe, but it is threatened with closure because of significantly cheaper Chinese competition and high energy and production costs. Despite EU funding to expand capacity, production is economically unviable according to Sandoz, which has therefore filed an anti-dumping investigation in Brussels against Chinese active ingredients. Closing the facility would massively increase Europe’s dependence on China for vital antibiotics and endanger supply security. » More on n-tv.de
Sandoz: investment a year ago would have returned 46.23%
Had 10,000 CHF been invested in Sandoz shares on 13 October 2025 (closing price 48.99 CHF), the value on 13 October 2026 would be 14,623.39 CHF (closing price 71.64 CHF), i.e. 46.23 percent higher. The calculation does not take stock splits or dividends into account. Sandoz's stock made its market debut on 4 October 2023 at an initial price of 24.00 CHF. » More on finanzen.net
Sandoz seeks preliminary approval in US for $400 million settlement
US states have asked a federal court in Connecticut for preliminary approval of a settlement with Sandoz over alleged price‑fixing for generics. The agreement covers 43 US jurisdictions and provides for total payments of $400 million over seven years, about $320.6 million as settlement principal and $79.4 million in interest. Sandoz and Fougera Pharmaceuticals, a subsidiary acquired in 2012, are accused of fixing prices and dividing markets; Sandoz denies the allegations. The first payment is due after final court approval, and no decision date has yet been set. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 4.94bn | - |
| Gross profit | 2.3bn | - |
| Net profit | 93.42m | - |
| EBITDA | 959.02m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €40.03bn |
Number of shares | 432.7m |
52-week high/low | €93.82 - €57.01 |
Dividend yield | 0.95% |
Dividends TTM | €0.87 |
Beta | 0.49 |
P/E ratio | 68.30 |
PEG ratio | 0.37 |
P/B ratio | 4.90 |
P/S ratio | 3.82 |
Company profile
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
| Name | Sandoz |
| CEO | Richard Saynor |
| Headquarters | Basel,
bs Switzerland |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 10/10/2023 |
| Employees | 23,000 |
Ticker symbols
| Exchange | Symbol |
|---|---|
London Stock Exchange | 0SAN.L |
SIX | SDZ.SW |
London | 0SAN.L |